Biolargo, INC. (BLGO) — 8-K Filings

8-K Filings (14)

• BioLargo, Inc. Files 8-K Report — Nov 18, 2025 Risk: low
  On November 14, 2025, BioLargo, Inc. filed an 8-K report detailing other events and financial statements. The company, formerly known as Nuway Medical Inc., is
• BioLargo, Inc. Files 8-K Report — Oct 20, 2025 Risk: low
  On October 20, 2025, BioLargo, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure and includes Financial Statements and Exhibits. No spec
• BioLargo, Inc. Terminates Material Agreement, Files 8-K — Sep 25, 2025 Risk: medium
  On September 19, 2025, BioLargo, Inc. reported the termination of a material definitive agreement. The company also disclosed material impairments and provided
• BioLargo, Inc. Files 8-K Report — Aug 15, 2025 Risk: low
  On August 15, 2025, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and the submission of financial statements and e
• BioLargo, Inc. Files Current 8-K Report — Jul 23, 2025 Risk: low
  On July 23, 2025, BioLargo, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 14921 Chestnut St., Westmins
• BioLargo Files 8-K on Shareholder Vote & Financials — Jun 25, 2025 Risk: low
  On June 19, 2025, BioLargo, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements. The company, form
• BioLargo, Inc. Files 8-K Report — Nov 15, 2024 Risk: low
  On November 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No speci
• BioLargo, Inc. Files 8-K Report — Aug 15, 2024 Risk: low
  On August 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. N
• BioLargo Files 8-K on Security Holder Vote & Exhibits — Jun 20, 2024 Risk: low
  On June 13, 2024, BioLargo, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The filing also includes financial state
• BioLargo Files 8-K Report — Jun 13, 2024 Risk: low
  On June 13, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• BioLargo Files 8-K: Regulation FD & Exhibits — May 15, 2024 Risk: low
  On May 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific f
• BioLargo Files Routine 8-K, Confirms OTCQB Listing — Jan 22, 2024
  BioLargo, Inc. filed an 8-K on January 22, 2024, primarily to disclose general information and confirm its status as a public company with Common Stock trading
• BioLargo Files 8-K for Regulation FD Disclosure, Financial Exhibits — Jan 10, 2024
  BioLargo, Inc. filed an 8-K on January 10, 2024, to disclose information under Regulation FD and to provide financial statements and exhibits. This filing indic
• BioLargo (BLGO) Changes Certifying Accountant on Jan 2 — Jan 5, 2024
  BioLargo, Inc. (BLGO) announced on January 2, 2024, that it has changed its certifying accountant, a significant event for investors. This change, reported in a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX